
Shares of telehealth provider Hims & Hers Health (NYSE: HIMS) sold off sharply following disappointing Q1 FY2026 financial results, with shares falling more than 12% in after-hours trading after the company reported on May 11.
Expectations for the quarter were high, particularly after partnering with Danish multinational pharmaceutical company Novo Nordisk (NYSE: NVO).